Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CSL ( (AU:CSL) ).
CSL Limited has notified the market that 59,992 conditional rights (ASX code: CSLAL) have lapsed after the performance or vesting conditions attached to those rights were not met or became incapable of being satisfied, effective 4 February 2026. The lapse reduces the pool of potential future CSL shares that could be issued under equity incentive arrangements, marginally tightening the company’s prospective share capital base and signalling that specific performance or service hurdles for those rights were not achieved.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$199.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company listed on the ASX, focused on developing and manufacturing biopharmaceutical products, including vaccines, plasma-derived therapies and specialty medicines for serious and rare diseases across international markets.
Average Trading Volume: 914,603
Technical Sentiment Signal: Sell
Current Market Cap: A$88.15B
See more insights into CSL stock on TipRanks’ Stock Analysis page.